Russian Federation
Russian Federation
Russian Federation
Secondary cardiorenal syndrome (CRS) in patients with type 2 diabetes is a combined cardiac and renal pathology with a combined and complex not fully understood pathogenesis, quickly leads to the death of the underlying disease. In this case, a violation of the function of one organ affects the functional state of another, and vice versa. An important role in the CRS pathogenesis is played renin-angiotensin-aldosterone system activation, leading to the progression of cardiac and renal hemodynamic disorders. The aim was to study the parameters of intrarenal hemodynamics and their relationship with the level of aldosterone and natriuretic peptide in patients with secondary cardiorenal syndrome in type 2 diabetes mellitus. In the course of the study, 48 patients with type 2 diabetes and secondary CRS were examined. There were 24 men and 24 women. The average age of the examined patients was 60.3 ± 7.5 years. The duration of type 2 diabetes in patients was 9.53±2.82 years. The control group consisted of 40 practically healthy volunteers matched by sex and age. The formation of secondary CRS in type 2 diabetes is accompanied by an increase concentrations of the N-terminal cerebral natriuretic propeptide (p <0.001) and aldosterone (p <0.001), the development of renal vascular remodeling and a decrease hemodynamic renal parameters. In patients with CRS and type 2 diabetes the presence of negative correlations between the level of aldosterone and the velocity indices of blood flow in the kidneys and a positive relationship with the indices of resistance of the renal arteries was found, as well as positive relationships between the level of NT-proBNP and indices of resistance in the vessels, negative - with speed indicators. In the course of multiple regression analysis, the influence of NT-proBNP and aldosterone levels on the predicted values of the peak velocity in the interlobular arteries (R2 = 0.30), glomerular filtration rate (R2 = 0.48) was established.
diabetes mellitus, cardiorenal syndrome, hemodynamics
1. Barbuk O. A. Kardiorenal'nyy sindrom: osnovnye problemy diagnostiki i lecheniya. Medicinskie novosti. 2018;3:60-65.
2. Glizer S. L. Ostraya dekompensaciya hronicheskoy serdechnoy nedostatochnosti i pochechnaya disfunkciya. Diagnostika, lechenie. Sibirskiy medicinskiy zhurnal. 2020;35(2):35-43.
3. Derevyanchenko M. V. Osobennosti kardiorenal'nyh vzaimootnosheniy u bol'nyh arterial'noy gipertenziey v sochetanii s saharnym diabetom 2 tipa. Terapiya. 2015;5:194.
4. Lopina E. A., Grishina N. P., Libis R. A. Arterial'naya gipertoniya kak trigger razvitiya kardiorenal'noy nedostatochnosti u pacientov raznogo pola. Sibirskiy zhurnal klinicheskoy i eksperimental'noy mediciny. 2019;34(3):114-121. doihttps://doi.org/10.29001/2073-8552-2019-34-3-114-121.
5. Sivozhelezova O. K., Ivanov K. M., Kunarbaev A. K., Chumakova N. S., Lazareva N. V. Osobennosti remodelirovaniya serdca i izmeneniy gemodinamiki u bol'nyh saharnym diabetom 2 tipa, oslozhnennym sindromom diabeticheskoy stopy. Sovremennaya nauka: aktual'nye problemy teorii i praktiki. Seriya: estestvennye i tehnicheskie nauki. 2018;4:169-172.
6. Shevelek A. N. Vzaimosvyaz' plazmennyh urovney al'dosterona i pokazateley uglevodnogo obmena pri hronicheskoy serdechnoy nedostatochnosti s sohranennoy frakciey vybrosa. Rossiyskiy kardiologicheskiy zhurnal. 2021;1(26):10-16. doihttps://doi.org/10.15829/1560-4071-2021-3991.
7. Bock J. S., Gottlieb S.S. Cardiorenal syndrome: new perspectives. Circulation.2010;121(23):2592-2600. doi:https://doi.org/10.1161/CIRCULATIONAHA.109.886473.
8. Fouli, G. E., Gnudi L. The future: experimental therapies for renal disease in diabetes. Nephron. 2019;143(1):3-7. doihttps://doi.org/10.1159/000492825.
9. Mann J. F. E. Orsted K. Liraglutide and renal outcomes in type 2 diabetes N Engl J Med. 2017;377:839-848. doihttps://doi.org/10.1056/NEJMoa1616011.
10. Nistala R., Whaley-Connell A. Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol. Cell. Endocrinol. 2013;378(1-2):53-58. doi:https://doi.org/10.1016/j. mce.2013.02.005.
11. Papademetriou V., Lovato L., Doumas M. et al. ACCORD Study Group: Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649-659. doi:https://doi.org/10.1038/ki.2014.296.
12. Rodrnguez-Jimynez A., Negrnn-Valdys T., Cruz-Inerarity H. et al. Cardiorenal syndrome as predictor of in-hospital mortality in ST-segment elevation myocardial infarction Clin Investig Arterioscler. 2018;30(4):163-169. doi: https://doi.org/10.1016/j. arteri.2017.12.005.
